Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations
Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim...
Gespeichert in:
| Veröffentlicht in: | Journal of nuclear cardiology 2023-10, Vol.30 (5), p.2089-2095 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2095 |
|---|---|
| container_issue | 5 |
| container_start_page | 2089 |
| container_title | Journal of nuclear cardiology |
| container_volume | 30 |
| creator | Mair, Braeden A. Zelt, Jason G.E. Nekesa, Kirabo Saint-Georges, Zacharie Dinelle, Katie Adi, Myriam Robinson, Simon Mielniczuk, Lisa M. Shlik, Jakov Beanlands, Rob S. deKemp, Robert A. Rotstein, Benjamin H. |
| description | Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.
Blood sampling was performed on 20 participants concurrent to FBBG PET imaging (healthy = NORM, non-ischemic cardiomyopathy = NICM, ischemic cardiomyopathy = ICM, post-traumatic stress disorder = PTSD). Image-derived blood time-activity curves were transformed to plasma input functions using cohort-specific corrections for plasma protein binding, plasma-to-whole blood distribution, and metabolism.
The plasma-to-whole blood ratio was 0.78 ± 0.06 for NORM, 0.64 ± 0.06 for PTSD and 0.60 ± 0.14 for (N)ICM after 20 minutes. 22 ± 4% of FBBG was bound to plasma proteins. Metabolism of FBBG in (N)ICM was delayed, with a parent fraction of 0.71 ± 0.05 at 10 minutes post-injection compared to 0.53 ± 0.03 for PTSD/NORM. While there were variations in metabolic rate, metabolite-corrected plasma input functions were similar across all cohorts.
Rapid plasma clearance of FBBG limits the impact of disease-specific corrections of the blood input function for tracer kinetic modeling. |
| doi_str_mv | 10.1007/s12350-023-03338-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2843034240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1071358124001351</els_id><sourcerecordid>2873784409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-b73766c8c5695a0e2408147338627e8e3617fa098c777d08eb896971a23df8213</originalsourceid><addsrcrecordid>eNp9kFFr1zAUxYMobvvrF_BBCr74Uk1y2yYBX2S4TRjMB30SCWl6WzPSpCatsG-_bJ0KPuwpCTnn3HN_hLxi9B2jVLzPjENLa8qhpgAga_WEHLMWeN21LXta7lSwGlrJjshJzteUUgVKPSdHIBrVig6Oif7y06TZ2Ojj5KzxlQlDNeNq-uidrRaTTHlhylUcq-9Mnv0Y_dan2GOYNhOwcqGy3oV7r5vN5MJULXHZvFldDPkFeTYan_Hlw3kg384-fT29qC-vzj-ffrysLQi11r0A0XVW2rZTraHIGypZI8pSHRcoETomRkOVtEKIgUrspeqUYIbDMErO4EDe7rlLir82zKueXbbofekYt6y5bIBCU3KL9M1_0uu4pVDaFVXpIZumcDoQvqtsijknHPWSyn7pRjOq7_DrHb8u-PU9fn1nev0QvfUzDn8tf3gXAeyCXL7ChOnf7EdjP-wuLAR_u-LK1mGwOLiEdtVDdI_ZbwHtwKJO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2873784409</pqid></control><display><type>article</type><title>Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Alma/SFX Local Collection</source><creator>Mair, Braeden A. ; Zelt, Jason G.E. ; Nekesa, Kirabo ; Saint-Georges, Zacharie ; Dinelle, Katie ; Adi, Myriam ; Robinson, Simon ; Mielniczuk, Lisa M. ; Shlik, Jakov ; Beanlands, Rob S. ; deKemp, Robert A. ; Rotstein, Benjamin H.</creator><creatorcontrib>Mair, Braeden A. ; Zelt, Jason G.E. ; Nekesa, Kirabo ; Saint-Georges, Zacharie ; Dinelle, Katie ; Adi, Myriam ; Robinson, Simon ; Mielniczuk, Lisa M. ; Shlik, Jakov ; Beanlands, Rob S. ; deKemp, Robert A. ; Rotstein, Benjamin H.</creatorcontrib><description>Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.
Blood sampling was performed on 20 participants concurrent to FBBG PET imaging (healthy = NORM, non-ischemic cardiomyopathy = NICM, ischemic cardiomyopathy = ICM, post-traumatic stress disorder = PTSD). Image-derived blood time-activity curves were transformed to plasma input functions using cohort-specific corrections for plasma protein binding, plasma-to-whole blood distribution, and metabolism.
The plasma-to-whole blood ratio was 0.78 ± 0.06 for NORM, 0.64 ± 0.06 for PTSD and 0.60 ± 0.14 for (N)ICM after 20 minutes. 22 ± 4% of FBBG was bound to plasma proteins. Metabolism of FBBG in (N)ICM was delayed, with a parent fraction of 0.71 ± 0.05 at 10 minutes post-injection compared to 0.53 ± 0.03 for PTSD/NORM. While there were variations in metabolic rate, metabolite-corrected plasma input functions were similar across all cohorts.
Rapid plasma clearance of FBBG limits the impact of disease-specific corrections of the blood input function for tracer kinetic modeling.</description><identifier>ISSN: 1071-3581</identifier><identifier>EISSN: 1532-6551</identifier><identifier>DOI: 10.1007/s12350-023-03338-9</identifier><identifier>PMID: 37495763</identifier><language>eng</language><publisher>Cham: Elsevier Inc</publisher><subject>Brief Report ; Cardiology ; Cardiomyopathies ; Cardiomyopathy ; Flubrobenguane ; fluorine-18 ; Guanidines ; Heart ; Humans ; Imaging ; Ischemia ; Medicine ; Medicine & Public Health ; Metabolism ; Metabolites ; Nuclear Medicine ; PET ; Plasma ; Positron-Emission Tomography - methods ; Post traumatic stress disorder ; Radiology ; sympathetic nervous system</subject><ispartof>Journal of nuclear cardiology, 2023-10, Vol.30 (5), p.2089-2095</ispartof><rights>2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved.</rights><rights>The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2023</rights><rights>2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.</rights><rights>The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2023.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-b73766c8c5695a0e2408147338627e8e3617fa098c777d08eb896971a23df8213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12350-023-03338-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12350-023-03338-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37495763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mair, Braeden A.</creatorcontrib><creatorcontrib>Zelt, Jason G.E.</creatorcontrib><creatorcontrib>Nekesa, Kirabo</creatorcontrib><creatorcontrib>Saint-Georges, Zacharie</creatorcontrib><creatorcontrib>Dinelle, Katie</creatorcontrib><creatorcontrib>Adi, Myriam</creatorcontrib><creatorcontrib>Robinson, Simon</creatorcontrib><creatorcontrib>Mielniczuk, Lisa M.</creatorcontrib><creatorcontrib>Shlik, Jakov</creatorcontrib><creatorcontrib>Beanlands, Rob S.</creatorcontrib><creatorcontrib>deKemp, Robert A.</creatorcontrib><creatorcontrib>Rotstein, Benjamin H.</creatorcontrib><title>Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations</title><title>Journal of nuclear cardiology</title><addtitle>J. Nucl. Cardiol</addtitle><addtitle>J Nucl Cardiol</addtitle><description>Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.
Blood sampling was performed on 20 participants concurrent to FBBG PET imaging (healthy = NORM, non-ischemic cardiomyopathy = NICM, ischemic cardiomyopathy = ICM, post-traumatic stress disorder = PTSD). Image-derived blood time-activity curves were transformed to plasma input functions using cohort-specific corrections for plasma protein binding, plasma-to-whole blood distribution, and metabolism.
The plasma-to-whole blood ratio was 0.78 ± 0.06 for NORM, 0.64 ± 0.06 for PTSD and 0.60 ± 0.14 for (N)ICM after 20 minutes. 22 ± 4% of FBBG was bound to plasma proteins. Metabolism of FBBG in (N)ICM was delayed, with a parent fraction of 0.71 ± 0.05 at 10 minutes post-injection compared to 0.53 ± 0.03 for PTSD/NORM. While there were variations in metabolic rate, metabolite-corrected plasma input functions were similar across all cohorts.
Rapid plasma clearance of FBBG limits the impact of disease-specific corrections of the blood input function for tracer kinetic modeling.</description><subject>Brief Report</subject><subject>Cardiology</subject><subject>Cardiomyopathies</subject><subject>Cardiomyopathy</subject><subject>Flubrobenguane</subject><subject>fluorine-18</subject><subject>Guanidines</subject><subject>Heart</subject><subject>Humans</subject><subject>Imaging</subject><subject>Ischemia</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Nuclear Medicine</subject><subject>PET</subject><subject>Plasma</subject><subject>Positron-Emission Tomography - methods</subject><subject>Post traumatic stress disorder</subject><subject>Radiology</subject><subject>sympathetic nervous system</subject><issn>1071-3581</issn><issn>1532-6551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFFr1zAUxYMobvvrF_BBCr74Uk1y2yYBX2S4TRjMB30SCWl6WzPSpCatsG-_bJ0KPuwpCTnn3HN_hLxi9B2jVLzPjENLa8qhpgAga_WEHLMWeN21LXta7lSwGlrJjshJzteUUgVKPSdHIBrVig6Oif7y06TZ2Ojj5KzxlQlDNeNq-uidrRaTTHlhylUcq-9Mnv0Y_dan2GOYNhOwcqGy3oV7r5vN5MJULXHZvFldDPkFeTYan_Hlw3kg384-fT29qC-vzj-ffrysLQi11r0A0XVW2rZTraHIGypZI8pSHRcoETomRkOVtEKIgUrspeqUYIbDMErO4EDe7rlLir82zKueXbbofekYt6y5bIBCU3KL9M1_0uu4pVDaFVXpIZumcDoQvqtsijknHPWSyn7pRjOq7_DrHb8u-PU9fn1nev0QvfUzDn8tf3gXAeyCXL7ChOnf7EdjP-wuLAR_u-LK1mGwOLiEdtVDdI_ZbwHtwKJO</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Mair, Braeden A.</creator><creator>Zelt, Jason G.E.</creator><creator>Nekesa, Kirabo</creator><creator>Saint-Georges, Zacharie</creator><creator>Dinelle, Katie</creator><creator>Adi, Myriam</creator><creator>Robinson, Simon</creator><creator>Mielniczuk, Lisa M.</creator><creator>Shlik, Jakov</creator><creator>Beanlands, Rob S.</creator><creator>deKemp, Robert A.</creator><creator>Rotstein, Benjamin H.</creator><general>Elsevier Inc</general><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20231001</creationdate><title>Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations</title><author>Mair, Braeden A. ; Zelt, Jason G.E. ; Nekesa, Kirabo ; Saint-Georges, Zacharie ; Dinelle, Katie ; Adi, Myriam ; Robinson, Simon ; Mielniczuk, Lisa M. ; Shlik, Jakov ; Beanlands, Rob S. ; deKemp, Robert A. ; Rotstein, Benjamin H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-b73766c8c5695a0e2408147338627e8e3617fa098c777d08eb896971a23df8213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Brief Report</topic><topic>Cardiology</topic><topic>Cardiomyopathies</topic><topic>Cardiomyopathy</topic><topic>Flubrobenguane</topic><topic>fluorine-18</topic><topic>Guanidines</topic><topic>Heart</topic><topic>Humans</topic><topic>Imaging</topic><topic>Ischemia</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Nuclear Medicine</topic><topic>PET</topic><topic>Plasma</topic><topic>Positron-Emission Tomography - methods</topic><topic>Post traumatic stress disorder</topic><topic>Radiology</topic><topic>sympathetic nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mair, Braeden A.</creatorcontrib><creatorcontrib>Zelt, Jason G.E.</creatorcontrib><creatorcontrib>Nekesa, Kirabo</creatorcontrib><creatorcontrib>Saint-Georges, Zacharie</creatorcontrib><creatorcontrib>Dinelle, Katie</creatorcontrib><creatorcontrib>Adi, Myriam</creatorcontrib><creatorcontrib>Robinson, Simon</creatorcontrib><creatorcontrib>Mielniczuk, Lisa M.</creatorcontrib><creatorcontrib>Shlik, Jakov</creatorcontrib><creatorcontrib>Beanlands, Rob S.</creatorcontrib><creatorcontrib>deKemp, Robert A.</creatorcontrib><creatorcontrib>Rotstein, Benjamin H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of nuclear cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mair, Braeden A.</au><au>Zelt, Jason G.E.</au><au>Nekesa, Kirabo</au><au>Saint-Georges, Zacharie</au><au>Dinelle, Katie</au><au>Adi, Myriam</au><au>Robinson, Simon</au><au>Mielniczuk, Lisa M.</au><au>Shlik, Jakov</au><au>Beanlands, Rob S.</au><au>deKemp, Robert A.</au><au>Rotstein, Benjamin H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations</atitle><jtitle>Journal of nuclear cardiology</jtitle><stitle>J. Nucl. Cardiol</stitle><addtitle>J Nucl Cardiol</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>30</volume><issue>5</issue><spage>2089</spage><epage>2095</epage><pages>2089-2095</pages><issn>1071-3581</issn><eissn>1532-6551</eissn><abstract>Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.
Blood sampling was performed on 20 participants concurrent to FBBG PET imaging (healthy = NORM, non-ischemic cardiomyopathy = NICM, ischemic cardiomyopathy = ICM, post-traumatic stress disorder = PTSD). Image-derived blood time-activity curves were transformed to plasma input functions using cohort-specific corrections for plasma protein binding, plasma-to-whole blood distribution, and metabolism.
The plasma-to-whole blood ratio was 0.78 ± 0.06 for NORM, 0.64 ± 0.06 for PTSD and 0.60 ± 0.14 for (N)ICM after 20 minutes. 22 ± 4% of FBBG was bound to plasma proteins. Metabolism of FBBG in (N)ICM was delayed, with a parent fraction of 0.71 ± 0.05 at 10 minutes post-injection compared to 0.53 ± 0.03 for PTSD/NORM. While there were variations in metabolic rate, metabolite-corrected plasma input functions were similar across all cohorts.
Rapid plasma clearance of FBBG limits the impact of disease-specific corrections of the blood input function for tracer kinetic modeling.</abstract><cop>Cham</cop><pub>Elsevier Inc</pub><pmid>37495763</pmid><doi>10.1007/s12350-023-03338-9</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1071-3581 |
| ispartof | Journal of nuclear cardiology, 2023-10, Vol.30 (5), p.2089-2095 |
| issn | 1071-3581 1532-6551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2843034240 |
| source | MEDLINE; SpringerLink Journals; Alma/SFX Local Collection |
| subjects | Brief Report Cardiology Cardiomyopathies Cardiomyopathy Flubrobenguane fluorine-18 Guanidines Heart Humans Imaging Ischemia Medicine Medicine & Public Health Metabolism Metabolites Nuclear Medicine PET Plasma Positron-Emission Tomography - methods Post traumatic stress disorder Radiology sympathetic nervous system |
| title | Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T13%3A52%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20and%20metabolic%20parameters%20of%20%5B18F%5Dflubrobenguane%20in%20clinical%20imaging%20populations&rft.jtitle=Journal%20of%20nuclear%20cardiology&rft.au=Mair,%20Braeden%20A.&rft.date=2023-10-01&rft.volume=30&rft.issue=5&rft.spage=2089&rft.epage=2095&rft.pages=2089-2095&rft.issn=1071-3581&rft.eissn=1532-6551&rft_id=info:doi/10.1007/s12350-023-03338-9&rft_dat=%3Cproquest_cross%3E2873784409%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2873784409&rft_id=info:pmid/37495763&rft_els_id=S1071358124001351&rfr_iscdi=true |